预约演示
更新于：2026-08-22
Clavulanic Acid
克拉维酸
更新于：2026-08-22
概要
基本信息
原研机构- |
在研机构- |
权益机构- |
最高研发阶段终止临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C8H9NO5 |
InChIKeyHZZVJAQRINQKSD-PBFISZAISA-N |
CAS号58001-44-8 |
关联
52
项与 克拉维酸 相关的临床试验ChiCTR2500112845
Effect of Vonoprazan-Amoxicillin Combined with Compound Lactobacillus acidophilus on Symptoms and Gut Microbiome in Patients with Functional Constipation
CTIS2025-522562-70-00
A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on 400 mg / 5 mL amoxicillin + 57 mg / 5 mL of clavulanic acid powder for oral suspension in healthy volunteers under fed conditions.
CTIS2025-521718-24-00
A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on two amoxicillin-clavulanic acid film-coated tablet formulations in healthy volunteers under fed conditions.
100 项与 克拉维酸 相关的临床结果
登录后查看更多信息
100 项与 克拉维酸 相关的转化医学
登录后查看更多信息
100 项与 克拉维酸 相关的专利（医药）
登录后查看更多信息
12,354
项与 克拉维酸 相关的文献（医药）2026-12-01MOLECULAR BIOLOGY REPORTS
High prevalence and co-existence of SHV and CTX-M genes in extensively drug-resistant (XDR) Gram-negative bacteria isolated from hospital settings in Faisalabad District, Pakistan
Article
作者: Shaukat, Amir ; Duarte, Tania Da Silva ; Sattar, Azfar ; Blaskovich, Mark A T ; Zuegg, Johannes ; Ahmad, Zaheer ; Ali, Aamir ; Sarwar, Yasra ; Shehzad, Khurram ; Abbas, Umair ; Sajjad, Huma
BACKGROUND: Hospital-acquired infections (HAIs) associated with increasing antimicrobial resistance (AMR) are becoming a global health challenge, causing AMR spread and a serious health threat. This study was designed to evaluate the phenotypic and genotypic status of AMR in Gram-negative HAI-associated bacteria, to gain a current insight into the local settings. METHODS AND RESULTS: Kirby-Bauer method and Double Disc Synergy Test were used for phenotypic assessment of AMR and extended-spectrum β-lactamase (ESBL) producers, respectively. Genes encoding antimicrobial resistance, ESBLs, and carbapenemases were identified by PCR followed by Sanger sequencing. Among 102 HAI samples, 62 were Gram-negative, identified as Escherichia coli (E. coli) (42.2%), Klebsiella pneumoniae (K. pneumoniae) (21.1%), and Pseudomonas aeruginosa (P. aeruginosa) (6.6%) by PCR. All K. pneumoniae and (95%) E. coli isolates exhibited multidrug resistance. K. pneumoniae isolates (95%) showed resistance against ceftazidime, cefotaxime, ceftriaxone, and aztreonam, and (89%) isolates were resistant to amoxicillin-clavulanic acid, ofloxacin, and cefepime (E. coli isolates (84%), (84%), (78%), (76%), (76%), and (73%) were resistant against cefotaxime, ceftriaxone, aztreonam, ceftazidime, doripenem, and colistin, respectively. Genotypically, the mcr-2 gene was detected in 5% K. pneumoniae isolates. Phenotypically, 63% isolates were identified as ESBL producers with high genetic prevalence of SHV-12 (78.9%) and SHV-1 (57.8%) in K. pneumoniae and CTX-M1 (60.5%) in E. coli. Notably, one K. pneumoniae isolate harbored all class-A ESBL genes, which is a novel finding. Co-existence of CTX-M1 + SHV-1 + TEM-1, SHV-1 + SHV-12 + TEM-1, and CTX-M1 + CTX-M15 + TEM-1 genes was dominant. CONCLUSION: The HAIs caused by extensively drug-resistant and ESBL-producing K. pneumoniae and E. coli were dominant, with less prevalence of moderately drug-resistant Pseudomonas isolates.
2026-12-01One Health
Genomic epidemiology to investigate the origins and zoonotic implications of antibiotic-resistant Escherichia coli on beef and lamb meat sold by independent butchers in Wales
Article
作者: Moiseienko, Yelyzaveta ; Mounsey, Oliver ; Peltonen, Noora ; Taylor, Jasmine ; Wright, Laura ; Sealey, Jordan E ; Williams, Philip ; Avison, Matthew B ; Llamazares, Beatriz
Many studies have identified antibiotic resistant (ABR) Escherichia coli on meat. Appropriate hand hygiene and cooking practices should minimize the risk of gastrointestinal colonisation with ABR E. coli found on meat, and the subsequent chance of causing resistant opportunistic extraintestinal infection. There are large gaps in our understanding of the prevalence, origins and zoonotic potential of ABR E. coli found on meat, however, and particularly for meat reared in extensive farming systems. Wales is a devolved nation within the United Kingdom having large populations of extensively-reared sheep and beef cattle. To help address knowledge gaps around ABR E. coli on extensively reared meat, therefore, beef mince and lamb loin/leg steaks/chops were purchased from 50 (beef) and 46 (lamb) independent butchers across Wales. Following enrichment culture, 200 g meat samples were found to be positive for E. coli resistant to amoxicillin (31% positivity), streptomycin (28%), spectinomycin (29%), amoxicillin-clavulanate (11%), 3rd generation cephalosporins (2%) and fluoroquinolones (5%). Phylogenetic analysis confirmed that Welsh lamb meat ABR E. coli isolates (n = 78) are more closely related to those found in faecal samples collected around sheep (n = 352) than around beef cattle (n = 361) on Welsh farms. This suggests that faecal contamination at or around slaughter is their primary origin. We found no closely related meat/infection clones (<20 SNPs distant and the same antibiotic resistance genes) when comparing ABR E. coli from Welsh meat (n = 91) and those causing extraintestinal infections in people (n = 2387) in an English region bordering Wales. We conclude, therefore, that the wider zoonotic implications of finding ABR E coli on beef and lamb meat sold at independent butchers in Wales are small, though a more geographically and temporarily contemporaneous survey is warranted to address this further.
2026-09-01Exploratory research in clinical and social pharmacy
Feasibility, fidelity and initial effects of an app-based service for short-term antibiotic therapy: A pilot study in a primary care setting
Article
作者: Sutter, Vanessa ; Arnet, Isabelle ; Messner, Kirstin ; Allemann, Samuel
Background:
Short-term antibiotic treatments show medication non-adherence rates around 40%, limiting therapy success and increasing risk for recurring infections. Smartphone applications offer simple solutions to support patients' medication adherence.
Objective:
To evaluate service and trial feasibility of a smartphone-based adherence support delivered by community pharmacists and to explore initial effects.
Methods:
We conducted a cluster-randomized pilot trial. Community pharmacies recruited eligible patients with newly prescribed amoxicillin/clavulanic acid therapy when dispensing the prescription. Participants used an app to confirm medication intakes. The intervention group received intake reminders and text messages. We evaluated feasibility and fidelity based on data quality, participant satisfaction, and extent to which service activities were delivered as planned. For exploratory analyses, we used the Mann-Whitney U test, and calculated effect sizes.
Results:
Fifty-seven community pharmacies and 34 patients participated in the study (17 per group). Twenty-nine participants (85%) fully completed the study. Twenty-one participants (62%) used and returned the symptom diary. For 30 participants (88%), the app was installed correctly and twenty-five (83%) participants consistently used the app. We observed small, non-significant effects for taking adherence (r = 0.158) and timing adherence (r = 0.147), and small-medium (r = 0.294) for dosing adherence.
Conclusion:
This study demonstrated feasibility and fidelity of a smartphone-based therapy support in the community pharmacy setting. Trends suggest a potential improvement in adherence rates through smartphone reminders and text messages. These findings highlight the need for a fully powered trial.
100 项与 克拉维酸 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 重度抑郁症 | 临床2期 | 美国 | 2009-01-01 | |
| 中度重度抑郁症 | 临床2期 | 美国 | 2009-01-01 | |
| 勃起功能障碍 | 临床2期 | 美国 | 2008-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 衊餘醖鬱壓壓獵選艱艱(夢願簾蓋顧淵網糧壓艱) = 憲鏇壓襯簾醖鬱願糧窪 繭顧繭憲遞糧築網鹽膚 (鬱製淵簾窪顧鑰餘窪積 ) | 积极 | 2025-08-12 | |||
临床1期 | - | 夢網製衊醖壓獵範築夢(獵衊網餘鹹鬱範構觸獵) = 蓋蓋製積繭築廠鬱願窪 夢構鹹壓獵鬱糧鹽醖鏇 (艱廠鏇鬱鬱艱衊製廠鏇 ) | 积极 | 2024-04-04 | |||
临床2期 | 112 | (Rifampin Resistant A) | 選簾糧膚築襯願襯壓構(蓋艱範範網夢醖鑰醖觸) = 衊襯選廠淵醖衊鑰選繭 願廠製遞衊觸糧淵糧夢 (鑰獵積醖願鑰蓋淵築鏇, 鬱獵鹽醖醖獵構淵鑰鹽 ~ 獵築衊衊網構鬱壓艱簾) 更多 | - | 2023-07-19 | ||
(Rifampin Resistant B) | 選簾糧膚築襯願襯壓構(蓋艱範範網夢醖鑰醖觸) = 繭鬱獵範鹹鏇壓襯糧觸 願廠製遞衊觸糧淵糧夢 (鑰獵積醖願鑰蓋淵築鏇, 範窪廠簾鏇獵願鏇餘糧 ~ 鏇蓋艱衊齋襯網網廠網) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用